Novartis Triple Combo Enerzair Gets EU OK For Asthma

Nudges Ahead Of GSK's Trelegy in Europe

The Swiss company's asthma triplet is now approved in Europe and Japan but Enerzair is well behind GSK's rival LABA/LAMA/ICS in the US where Novartis's product has not even been submitted yet.

Darts
Trebles all round at Novartis with Enerzair approval • Source: Shutterstock

Novartis AG's three-drug asthma therapy Enerzair Breezhaler, which comes with a digital sensor and app, has been given the green light in Europe, giving the Swiss major a significant headstart over GlaxoSmithKline plc's rival triple combination treatment Trelegy.

Enerzair, formerly known as QVM149, consists of long-acting beta agonist (LABA) indacaterol, the long-acting muscarinic antagonist (LAMA) glycopyrronium and the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category